The global survival rate after hematopoietic stem-cell transplantation among IKBKG-deficient children was 74% at a median follow-up after hematopoietic stem-cell transplantation of 57 months, and most of the clinical symptoms caused by IKBKG mutation were curable, except for colitis.84 The gene discussed is IKBKG; the disease is colitis.